Revvity, Inc.

RVTY · NYSE · Stock · Healthcare
$153.78
-0.84% today
Delayed price,

What Revvity does

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Key facts

Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$17.16B
P/E (ttm)
73.6
Forward P/E
26.1
Dividend yield
0.18%
Beta
1.06
Profit margin
8.2%
Employees
11,000
Headquarters
Waltham, MA, United States
Exchange
NYSE

Performance

1 Month
+7.2%
3 Months
+39.6%
6 Months
+63.7%
1 Year
+64.6%
5 Years
-15.6%
$81.2252-week range$166.25
Biggest setback — last 12 months
-28.1%
19 Jan 2026 → 23 Mar 2026
Fell from $116.73 to $83.90 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+84.8%
23 Mar 2026 → 12 Oct 2026
Ran from $83.90 to $155.08 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$137.77 (-10.4%)$153.78$171.64 (+11.6%)
3 Months$127.12 (-17.3%)$153.78$186.02 (+21.0%)
6 Months$117.48 (-23.6%)$153.78$201.29 (+30.9%)
12 Months$105.08 (-31.7%)$153.78$225.03 (+46.3%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 38.1%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Sold 84 shares at $155.48 — Gonzales Anita, VP and CAO · 2026-10-02
Sold 1,631 shares at $144.53 — Krakowiak Maxwell, Please See Remarks · 2026-09-23
Sold 7,330 shares at $140.88 — Vohra Tajinder S, Please See Remarks · 2026-09-18
Sold 285 shares — MICHAS ALEXIS P, Director · 2026-08-25
Acquired 55,570 shares — Goldberg Joel S, Please See Remarks · 2026-08-18
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.